You are here

Publications

Found 15 results
Sort by: Author Title [ Type (Asc)] Year
Filters: Author is M. Delorenzi  [Clear All Filters]
Book Chapter
Haibe-Kains B, Desmedt C, Loi S, Delorenzi M, Sotiriou C, Bontempi G. Computational Intelligence in Clinical Oncology : Lessons Learned from an Analysis of a Clinical Study. In: Applications of Computational Intelligence in Biology. Vol. 122. Applications of Computational Intelligence in Biology. ; 2008. p. 237-268.
Conference Paper
Sotiriou C, Wirapati P, Loi S, Desmedt C, Durbecq V, Harris A, Bergh J, Smeds J, Haibe-Kains B, Larsimont D, et al. Better characterization of estrogen receptor (ER) positive luminal subtypes using genomic grade. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S19.
Sotiriou C, Desmedt C, Haibe-Kains B, Harris A, Larsimont D, Buyse M, Wirapati P, Delorenzi M, Bontempi G, Piccart MJ, et al. Biological mechanisms that trigger breast cancer (BC) tumor progresion are molecular subtype dependent.
Sotiriou C, Wirapati P, Loi SM, Desmedt C, Durbecq V, Harris A, Bergh J, Smeds J, Haibe-Kains B, Larsimont D, et al. Breast tumours with intermediate histological grade can be reclassified into prognostically distinct groups by gene expression profiling. In: Breast Cancer Research and Treatment. Vol. 94. Breast Cancer Research and Treatment. ; 2005. p. S30.
Sotiriou C, Wirapati P, Loi S, Haibe-Kains B, Desmedt C, Tutt A, Ellis P, Buyse M, Delorenzi M, Piccart M, et al. Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1500 samples: Proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer (BC).
Sotiriou C, Haibe-Kains B, Desmedt C, Wirapati P, Durbecq V, Harris A, Larsimont D, Bontempi G, Buyse M, Delorenzi M, et al. Comprehensive molecular analysis of several prognostic signatures using molecular indices related to hallmarks of breast cancer: proliferation index appears to be the most significant component of all signatures.
Sotiriou C, Wirapati P, Loi S, Harris A, Bergh J, Smeds J, Farmer P, Praz V, Haibe-Kains B, Lallemand F, et al. Gene Expression Profiling in Breast Cancer Challenges the Existence of Intermediate Histological Grade.
Sotiriou C, Wirapati P, Loi S, Haibe-Kains B, Piette F, Buyse M, Bontempi G, Delorenzi M, Piccart M. Is genomic grading killing histological grading ?. In: Journal of European Breast Cancer. Vol. 4. Journal of European Breast Cancer. ; 2006. p. 177.
Desmedt C, Piette F, Cardoso F, Wang Y, Loi S, Lallemand F, Klijn J, Haibe-Kains B, Viale G, Delorenzi M, et al. TRANSBIG multi-centre independent validation of the Rotterdam 76-gene prognostic signature for patients with node-negative breast cancer.
Journal Article
Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes. Clin Cancer Res [Internet]. 2008:5158-5165.
Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt A, Gillett C, Harris A, Bergh J, Foekens J, Klijn J, et al. Definition of clinically distinct molecular subtypes in estrogen receptor positive breast carcinomas through use of genomic grade. Journal of Clinical Oncology. 2007.
Sotiriou C, Wirapati P, Loi SM, Desmedt C, Durbecq V, Harris A, Bergh J, Smeds J, Haibe-Kains B, Larsimont D, et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. Journal of National Cancer Institute. 2006:262-272.
Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Research [Internet]. 2008:R65.
Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt A, Gillet C, Ellis P, Ryder K, Reid J, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics [Internet]. 2008:239.
Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, Saghatchian d'Assignies M, et al. Strong time-dependency of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multi-centre independent validation series. Clinical Cancer Research. 2007:3207-14.

Theme by Danetsoft and Danang Probo Sayekti inspired by Maksimer